RE: Oxford vaccine19 Nov 2020 07:15
Yes brilliant news for us ! Need to align ourselves with them with our tests
( more tests that way )
From the investor Q & A’s
Omega welcomes the recent interim analysis re. the Pfizer/BioNTech COVID-19 vaccine candidate and news that we may be closer to an effective vaccine. Antibody testing, and the AbC-19 Rapid Test in particular, can play what the Company believes to be an instrumental role in assessing initial immune responses, and in determining where follow-up or booster campaigns may be needed.
The role of antibody testing is also likely to provide a long term use of the tests and given the number of vaccines worldwide presents a considerable opportunity.
What opportunities are there to sell the ABC-19 antibody tests beyond the UK and will this generate better margins for Omega Diagnostics than with the UK RTC?
The Company is confident there is a significant opportunity to sell the ABC-19 antibody tests beyond the UK, due to product performance, and its link to the UK Government.
The consortium is actively looking at other markets across the world including the US and yes this will generate better margins.
I just hope we have a bigger enough factory!?